"Gerald E. Commissiong, President & CEO of Amarant
Post# of 30066
Posted On: 02/05/2015 10:46:54 PM
"Gerald E. Commissiong, President & CEO of Amarantus, will provide a corporate update and a review of the Amarantus Diagnostics business and development strategy for the company's therapeutic programs with a focus on investigational drug, eltoprazine, for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LID) , on Tuesday, February 10, 2015, at 8:30 a.m. Eastern Standard Time."
Near Term Catalysts:
IND Submission / Approval; Phase 2b in PD LID; End of Phase 2 meeting in Adult ADHD
Near-term Q1 Milestones Expected to Build Significant Momentum
Eltoprazine: IND submission
Eltoprazine: Initiate Phase 2b clinical trials
Investment Summary
Eltoprazine: Phase 2b-ready small molecule for PD LID
• Over 680 patients dosed to date, with strong safety profile
• Phase 2b initiation in process
http://content.stockpr.com/amarantus/media/23...9c4a0e.pdf (Slides 7, 56, 58)
Near Term Catalysts:
IND Submission / Approval; Phase 2b in PD LID; End of Phase 2 meeting in Adult ADHD
Near-term Q1 Milestones Expected to Build Significant Momentum
Eltoprazine: IND submission
Eltoprazine: Initiate Phase 2b clinical trials
Investment Summary
Eltoprazine: Phase 2b-ready small molecule for PD LID
• Over 680 patients dosed to date, with strong safety profile
• Phase 2b initiation in process
http://content.stockpr.com/amarantus/media/23...9c4a0e.pdf (Slides 7, 56, 58)
(0)
(0)